...
首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Development of a fibrin composite-coated poly(epsilon-caprolactone) scaffold for potential vascular tissue engineering applications.
【24h】

Development of a fibrin composite-coated poly(epsilon-caprolactone) scaffold for potential vascular tissue engineering applications.

机译:纤维蛋白复合涂层聚(ε-己内酯)支架的开发,用于潜在的血管组织工程应用。

获取原文
获取原文并翻译 | 示例
           

摘要

Poor cell adhesion, cytotoxicity of degradation products and lack of biological signals for cell growth, survival, and tissue generation are the limitations in the use of a biodegradable polymer scaffold for vascular tissue engineering. We have fabricated a hybrid scaffold by integrating physicochemical characteristics of poly(epsilon-caprolactone) (PCL) and biomimetic property of a composite of fibrin, fibronectin, gelatin, growth factors, and proteoglycans to improve EC growth on the scaffold. Solvent cast porous films of poly(epsilon-caprolactone) was prepared using PEG as a porogen. Porosity varied between 5 and 200 microm, and FTIR spectroscopy confirmed structural aspects of PCL. Films kept in PBS for 60 days showed tensile strength and elongation matching native blood vessel. Slow degradation of the scaffold was demonstrated by gravimetric analysis and molecular weight determination. Human umbilical vein endothelial cell (HUVEC) adhesion and proliferation on bare films were minimal. FTIR spectroscopy and environmental scanning electron microscopy (ESEM) of PCL-fibrin hybrid scaffold confirmed the presence of fibrin composite on PCL film. HUVEC was subsequently cultured on hybrid scaffold, and continuous EC lining was observed in 15 and 30 days of culture using ESEM. Results suggest that the new hybrid scaffold can be a suitable candidate for cardiovascular tissue engineering.
机译:在将可生物降解的聚合物支架用于血管组织工程中的应用中,局限性在于细胞粘附力差,降解产物的细胞毒性以及缺乏细胞生长,存活和组织生成的生物学信号。我们通过整合聚(ε-己内酯)(PCL)的理化特性和纤维蛋白,纤连蛋白,明胶,生长因子和蛋白聚糖的复合物的仿生特性来改善支架上的EC生长,从而制造了一种混合支架。使用PEG作为致孔剂制备了聚(ε-己内酯)的溶剂流延多孔膜。孔隙率在5到200微米之间变化,并且FTIR光谱证实了PCL的结构方面。在PBS中保存60天的薄膜显示出与天然血管相匹配的拉伸强度和伸长率。重量分析和分子量测定证明了支架的缓慢降解。人脐静脉内皮细胞(HUVEC)在裸膜上的粘附和增殖极小。 PCL-纤维蛋白混合支架的FTIR光谱和环境扫描电子显微镜(ESEM)证实了PCL膜上存在纤维蛋白复合物。随后在混合支架上培养HUVEC,并使用ESEM在15和30天的培养中观察到连续的EC衬里。结果表明,新的混合支架可以是心血管组织工程的合适候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号